RNTein Biotechnology and Mechanism-based Cancer Treatments
RNTein Biotech Laboratory is a new enterprise in the field of human cancer gene therapy. RNTein Biotech focuses specifically on developing mechanism-based therapeutic products for the treatment of cancer.
Cancer was once termed a "severe genome malfunction" resulting from mutations, however researchers are now realizing that the tumor environment is itself a coconspirator. A variety of cells in and around tumors help cancer cells survive, grow, and metastasize. Scientists have already found several agents such as MDSCs and TAFs that aid in the development of common solid tumors.
The purpose of cancer treatment is to not only kill cancerous cells, but also to block these harmful agents while protecting normal cells. Currently, conventional cancer treatments may actually damage normal cells and can even stimulate the production of MDSCs or TAFs in the course of treatment. However, RNTein Biotech Laboratory has developed a novel cancer treatment approach.
The relatively recent discovery of RNA interference (RNAi) has helped shed light on the use of short RNA molecules, dubbed mircoRNAs or miRNAs, to regulate gene expression. Lately, miRNAs are garnering attention in the biomedical front. miRNAs are believed to regulate the expression of some human genes and have been implicated in the proliferation, differentiation, and apoptosis of human cells. In cancerous growths, tumor cells experience a loss of miRNA expression, and this reduction of global miRNA expression promotes the transformation of new cancerous cells.
Recent clinical trials have focused on exploiting this RNA interference phenomenon in order to shut down DNA replicative genes that cause cancer cell proliferation. Human Cdc6, homologous to highly conserved yeast DNA replicative protein, is essential for the initiation of DNA replication. Cdc6 depletion through the use of Cdc6 siRNAs has been shown to induce apoptosis in human hepatocarcinoma cell lines and cervical carcinoma HeLa cells.